Sanara MedTech Q4 Earnings Call Highlights

Core Insights - Sanara MedTech reported record annual revenue of $103.1 million in 2025, marking a 19% increase year over year, while achieving improved profitability metrics and operational performance [3][4][7]. Financial Performance - The company generated $6.8 million in cash from operations in 2025, a significant improvement from a cash usage of $24,000 in 2024, attributed to better operating performance and working capital management [1]. - Gross margin improved by approximately 200 basis points to 93% for the full year, with adjusted EBITDA rising by $7.9 million, or 86%, to $17 million [2][7]. - The net loss from continuing operations decreased by $1.5 million, or 80%, compared to the previous year [2]. Revenue Breakdown - For the fourth quarter of 2025, net revenue was $27.5 million, up 5% year over year, primarily driven by sales of soft tissue products [7][8]. - Excluding the impact of prior year sales related to Hurricane Helene, fourth-quarter 2025 net revenue increased by 13% year over year [8]. Commercial Strategy - The company ended 2025 with over 450 contracted distributors, up from over 350 at the end of 2024, and achieved sales in over 1,450 healthcare facilities [9][10]. - Sanara secured an Innovative Technology contract from Vizient, providing access to approximately 1,800 healthcare facilities [12]. Operational Updates - The wind-down of the Tissue Health Plus (THP) segment is substantially complete, with no material cash expected going forward [5][11]. - The company anticipates no material cash spend related to THP and reaffirmed its 2026 net revenue guidance of $116 million to $121 million, representing expected growth of approximately 13% to 17% [5][20]. Clinical and Intellectual Property Developments - Sanara is focused on building clinical evidence, with studies demonstrating the efficacy of its products, including BIASURGE and ALLOCYTE Plus [13]. - The company converted 11 provisional patent applications into non-provisional filings and submitted additional applications for international protection [14]. Future Outlook - The company expects first-quarter 2026 net revenue of approximately $26.7 million to $27.2 million, implying expected year-over-year growth of about 14% to 16% [20]. - Management emphasized the importance of educating facilities on the Vizient contract for future growth [21].